Under the draft determination, the test would be covered to help assess which treatments to use in patients with advanced prostate cancer.
The company saw a drop in its Q4 sample accessions compared to the same quarter last year, but posted increases in both testing and revenues for the full year.
Angle aims to show that clinicians can determine HER-2 status by subjecting harvested circulating tumor cells to fluorescence in situ hybridization (FISH).
Liquid biopsy companies are increasingly recognizing the value of analyzing not just circulating tumor DNA, but biomarkers like CTCs, methylation, and proteins.
The two companies intend to develop and commercialize several cancer and NIPT assays using a combination of their technologies.
The company plans to continue to validate the liquid biopsy system for use in cancer diagnostics, therapy management, and patient monitoring.
This is Biocept's third BCBS contract and enables cancer patients to access the company's testing services in network under their Wellmark health plans.
The new European initiative promises to deliver multiple new tests and methods for improving the treatment of breast cancer and rectal cancer.
The companies will comarket Clearbridge's ClearCell CTC system and Leica's Bond Rx staining platform.
The company believes its system, launched earlier this year, can outperform other microfluidic technologies, yielding samples with fewer white blood cells that allow better genomic analyses.
A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.
A new analysis finds some cancers receive more nonprofit dollars than others.
An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.
In Science this week: comparative analysis of sex differences in mammal gene expression, and more.